Posted by Michael Wonder on 26 Aug 2022
Stakeholders ask FDA to be more flexible on rescinding breakthrough drug designations
26 August 2022 - Pharmaceutical stakeholders want the US FDA to be more flexible when revoking breakthrough therapy designations.
In comments on a recent draft guidance, they made several suggestions including allowing breakthrough drugs to stay on the market in certain cases even if an alternative treatment becomes available.
